Main Industry
Biotechnology
Main Product/Service
Immunwork’s lead technology pipeline consists of ultra‑long‑acting peptides (via a fatty acid bundle platform), as well as antibody‑drug conjugates (ADCs) and antibody‑radionuclide conjugates (ARCs). These T‑E™ molecules leverage multi-arm linkers and tar
Founded Year
2014
Unified Business No.
24760917
Status
Active
Number of Employees
0
Total Paid-in
Capital
717,075,700 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Immunwork, Inc., founded in 2014 in Taipei, is a biotech company developing new drug entities using its proprietary T‑E™ pharmaceuticals platform, which integrates targeting (T) and effector (E) functions to enhance both efficacy and safety. The company is advancing treatments for conditions such as diabetes, obesity, tumors, clots, and other serious diseases.
Corporate Video
